Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Iron--potential therapeutic target in hemorrhagic stroke.

Chaudhary N, Gemmete JJ, Thompson BG, Xi G, Pandey AS.

World Neurosurg. 2013 Jan;79(1):7-9. doi: 10.1016/j.wneu.2012.11.048. Epub 2012 Nov 19. No abstract available.

PMID:
23174156
2.

Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage.

Nakamura T, Keep RF, Hua Y, Schallert T, Hoff JT, Xi G.

Neurosurg Focus. 2003 Oct 15;15(4):ECP4.

PMID:
15344903
3.

Bipyridine, an iron chelator, does not lessen intracerebral iron-induced damage or improve outcome after intracerebral hemorrhagic stroke in rats.

Caliaperumal J, Wowk S, Jones S, Ma Y, Colbourne F.

Transl Stroke Res. 2013 Dec;4(6):719-28. doi: 10.1007/s12975-013-0272-3. Epub 2013 Aug 6.

PMID:
24323426
4.

Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials.

Selim M.

Stroke. 2009 Mar;40(3 Suppl):S90-1. doi: 10.1161/STROKEAHA.108.533125. Epub 2008 Dec 8. Review.

5.

High-dose intravenous chelation therapy with deferoxamine.

Cohen A, Mizanin J, Schwartz E.

Prog Clin Biol Res. 1989;309:125-31. No abstract available.

PMID:
2780746
6.

[Comparative evaluation of two models of hemosiderosis for analysis of iron chelators].

Minina LT, Prostakova TM, Meshchano AIu, Kol'tsova GN, Bovenko VN.

Biull Eksp Biol Med. 1996 Sep;122(9):359-60. Russian. No abstract available.

PMID:
8974501
7.

Deferoxamine reduces CSF free iron levels following intracerebral hemorrhage.

Wan S, Hua Y, Keep RF, Hoff JT, Xi G.

Acta Neurochir Suppl. 2006;96:199-202.

PMID:
16671454
8.

[Iron chelators].

Villegas A.

Med Clin (Barc). 1994 May 21;102(19):739-41. Spanish. No abstract available.

PMID:
8041203
9.

[Effect of desferal therapy on indices of iron metabolism in patients with intermediate forms of beta-thalassemia].

Efendieva EG, Dashkova NG.

Gematol Transfuziol. 1987 Sep;32(9):23-6. Russian. No abstract available.

PMID:
3692120
10.

Iron chelation therapy for iron loaded patients.

Jacobs A.

Br J Haematol. 1979 Sep;43(1):1-5. Review. No abstract available.

PMID:
389274
11.

Iron accumulation and DNA damage in a pig model of intracerebral hemorrhage.

Gu Y, Hua Y, He Y, Wang L, Hu H, Keep RF, Xi G.

Acta Neurochir Suppl. 2011;111:123-8. doi: 10.1007/978-3-7091-0693-8_20.

PMID:
21725742
12.

Deferoxamine therapy for intracerebral hemorrhage.

Hua Y, Keep RF, Hoff JT, Xi G.

Acta Neurochir Suppl. 2008;105:3-6. Review.

PMID:
19066072
13.

Role of deferoxamine in tumor therapy.

Donfrancesco A, Deb G, De Sio L, Cozza R, Castellano A.

Acta Haematol. 1996;95(1):66-9. Review.

PMID:
8604589
14.

Deferiprone: greater efficacy at depleting myocardial than hepatic iron?

Richardson DR.

Lancet. 2002 Aug 17;360(9332):501-2. No abstract available.

PMID:
12241649
15.

Iron and early brain injury after subarachnoid hemorrhage.

Loftspring MC.

J Cereb Blood Flow Metab. 2010 Nov;30(11):1791-2. doi: 10.1038/jcbfm.2010.139. Epub 2010 Aug 25.

16.

Iron chelation with oral deferiprone in patients with thalassemia.

Cohen AR, Martin MB.

N Engl J Med. 1998 Dec 3;339(23):1713-4. No abstract available.

PMID:
9867542
17.

An update on disordered iron metabolism and iron overload.

Ward R.

Hematology. 2010 Oct;15(5):311-7. doi: 10.1179/102453310X12647083621164. Review.

PMID:
20863426
18.

Iron chelators for thalassaemia.

Hershko C, Konijn AM, Link G.

Br J Haematol. 1998 Jun;101(3):399-406. Review. No abstract available.

PMID:
9633877
19.

Iron chelation.

Chandy M.

J Assoc Physicians India. 1991 Sep;39(9):665-6. No abstract available.

PMID:
1814896
20.

Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.

Kontoghiorghes GJ, Kolnagou A.

Lancet. 2003 Jan 11;361(9352):184. No abstract available.

PMID:
12531621

Supplemental Content

Support Center